type
interferon
ifn
activ
subsequ
effect
import
respons
viral
infect
show
human
astrovirus
hastv
import
agent
acut
gastroenter
children
induc
mild
delay
ifn
respons
upon
infect
cell
although
mrna
detect
within
infect
cell
supernat
infect
cell
show
antivir
activ
replic
wellknown
ifnsensit
virus
respons
occur
late
stage
infect
genom
replic
taken
place
hand
hastv
replic
partial
reduc
addit
exogen
ifn
inhibit
ifn
activ
enhanc
viral
replic
indic
hastv
ifnsensit
virus
final
differ
level
ifn
respons
observ
cell
infect
differ
hastv
mutant
chang
hypervari
region
suggest
genotyp
may
potenti
clinic
implic
due
correl
viral
replic
phenotyp
antivir
respons
induc
within
infect
cell
astrovirus
first
identifi
appleton
higgin
associ
outbreak
infantil
gastroenter
matern
ward
england
astrovirida
famili
today
contain
virus
infect
anim
speci
human
astrovirus
hastv
recogn
common
viral
pathogen
caus
gastroenter
infant
young
children
report
hastvmedi
diseas
normal
healthi
adult
report
sever
diseas
dissemin
extraintestin
tissu
immunocompromis
patient
astrovirus
nonenvelop
positivestrand
rna
virus
contain
kb
polyadenyl
genom
link
vpg
protein
genom
contain
three
overlap
open
read
frame
orf
encod
viral
proteas
polymeras
respect
encod
capsid
precursor
nonstructur
protein
nsp
translat
genom
rna
two
larg
knowledg
host
respons
hastv
may
provid
key
prevent
treatment
human
diseas
ecacc
hela
atcc
atcc
vero
atcc
cell
grown
eagl
minimum
essenti
medium
mem
supplement
fetal
bovin
serum
fb
cell
cultureadapt
strain
serotyp
hastv
kindli
provid
wd
cubitt
great
ormond
street
hospit
london
well
three
serotyp
hastv
mutant
differ
gene
hastviv
hastvvi
hastv
xii
use
studi
propag
prepar
hastv
stock
perform
previous
describ
briefli
virus
pretreat
trypsin
gix
sigma
per
ml
min
dilut
mem
fb
order
obtain
multipl
infect
moi
requir
experi
cell
monolay
wash
twice
mem
fb
inocul
viru
adsorpt
cell
wash
mem
fb
ad
order
ensur
singl
cycl
viral
replic
infecti
titer
stock
determin
cellcultur
rtpcr
method
previous
describ
immunofluoresc
analysi
infect
monolay
encephalomyocard
viru
emcv
rotaviru
rv
atcc
grown
hela
cell
respect
infecti
viral
titer
measur
assay
vero
cell
cell
respect
hastv
stock
inactiv
incub
h
room
temperatur
class
ii
biolog
safeti
cabinet
uv
light
complet
viral
inactiv
confirm
lack
capsid
protein
express
immunofluoresc
infect
cell
synthet
analog
dsrna
polyinosinepolycytidyl
acid
polyi
c
inhibitor
purchas
invivogen
dissolv
dmso
store
mm
solut
recombin
human
ifn
type
human
purchas
sigma
aldrich
mab
specif
capsid
protein
hastv
kindli
provid
rbiopharm
ag
polyclon
antibodi
hastv
kindli
provid
dr
dm
bass
depart
pediatr
stanford
univers
usa
rabbit
polyclon
purchas
santa
cruz
biotechnolog
label
goat
antimous
igg
amersham
ge
healthcar
alexa
label
antirabbit
igg
sigma
use
secondari
antibodi
immunofluoresc
analysi
rna
isol
rtpcr
quantit
realtim
rtpcr
qrtpcr
total
rna
cell
prepar
use
trizol
ls
reagent
invitrogen
follow
manufactur
instruct
remov
trace
contamin
dna
extract
rna
treat
u
rnasefre
dnase
promega
h
dnase
heat
inactiv
min
convent
rtpcr
reaction
detect
hastv
rna
gapdh
dehydrogenas
mrna
perform
use
expand
revers
transcriptas
expand
high
fidel
pcr
system
roch
hastv
genom
amplif
perform
use
primer
describ
previous
gapdh
mrna
amplif
perform
use
primer
describ
elsewher
quantit
realtim
rtpcr
assay
carri
use
instrument
stratagen
primer
probe
hastv
genom
quantif
target
region
previous
describ
standard
curv
hastv
rna
quantif
includ
everi
assay
gener
use
plasmid
contain
complet
genom
access
number
kindli
provid
dr
sm
matsui
va
palo
alto
health
care
system
palo
alto
usa
quantif
gapdh
mrna
primer
probe
design
use
realtim
pcr
assay
design
tool
integr
dna
technolog
idt
websit
specif
primer
probe
aag
gcc
aag
gag
tac
agg
cta
gga
gat
ctt
gat
ttc
cac
tct
gac
tat
ggt
cca
gapdh
specif
primer
probe
tcg
ctc
aga
cac
tca
ttg
atg
gca
aaa
tcc
gtt
gac
tcc
gac
ctt
gapdh
quantif
standard
curv
construct
everi
assay
use
serial
dilut
rna
sampl
correspond
posit
neg
control
experi
respect
gapdh
mrna
titer
use
endogen
control
normal
sampl
versu
number
cell
sampl
quantifi
least
duplic
reaction
perform
use
one
step
rt
qpcr
mastermix
plu
kit
eurogentec
thermal
protocol
consist
min
follow
min
cycl
min
virusinfect
cell
grown
glass
coverslip
plate
rins
twice
phosphat
buffer
salin
pb
stain
immunofluoresc
previous
describ
sampl
analyz
fluoresc
microscop
leica
dmrb
fluo
mean
percentag
infect
cell
calcul
field
coverslip
analyz
imag
use
imagej
softwar
amount
antivir
activ
secret
cell
estim
use
bioassay
hela
cell
perform
assay
supernat
hastvinfect
transfect
cell
uvinactiv
hela
cell
grown
plate
pretreat
dilut
inactiv
supernat
sampl
h
infect
emcv
moi
develop
emcvinduc
cytopath
effect
cpe
monitor
h
postinfect
hpi
cell
pretreat
dilut
cultur
media
contain
uml
recombin
type
ifn
use
refer
control
level
antivir
activ
express
rel
indirect
enzymelink
immunoassay
perform
serial
dilut
sampl
astroviru
antigen
cell
lysat
captur
mab
detect
use
rabbit
polyclon
antihastv
antibodi
specif
bound
antibodi
reveal
peroxidaseconjug
antirabbit
igg
antibodi
sigma
aldrich
undilut
cell
lysat
mockinfect
cultur
use
neg
control
calcul
posit
cutoff
valu
mean
standard
deviat
sampl
dilut
od
valu
higher
cutoff
valu
consid
posit
cell
differenti
day
semiperm
tissu
cultur
insert
pore
size
corn
incorpor
cell
cultur
medium
renew
altern
day
transepitheli
resist
ter
confirm
least
oxcm
use
evom
voltomet
world
precis
instrument
sarasota
fl
infect
monitor
everi
hour
cours
infect
result
present
percentag
insert
ter
read
versu
hpi
comparison
mean
perform
use
student
ttest
unpair
use
ibm
spss
statist
version
softwar
spss
inc
chicago
il
usa
p
valu
consid
statist
signific
examin
whether
hastv
infect
induc
ifn
respons
cell
infect
moi
rna
extract
hpi
fig
mockinfect
cell
cell
transfect
polyi
c
cell
treat
uml
recombin
type
ifn
use
control
convent
rtpcr
perform
detect
viral
rna
mrna
mrna
gapdh
mrna
amplifi
qualiti
control
rna
result
show
polyi
c
transfect
induc
gene
transcript
earli
hour
posttransfect
hpt
mrna
could
detect
hastvinfect
cell
hpi
time
cours
analysi
hastv
rna
synthesi
perform
qrtpcr
infect
cell
differ
moi
expect
increas
viral
rna
titer
observ
first
hour
moi
fig
togeth
result
suggest
hastv
delay
onset
ifn
induct
suffici
larg
amount
progeni
particl
produc
express
mrna
accumul
cell
treat
exogen
ifn
polyi
ctransfect
cell
start
h
fig
detect
mrna
hastvinfect
cell
hpi
could
indic
alreadi
releas
extracellular
media
although
also
describ
virus
divers
famili
induc
synthesi
mrna
absenc
ifn
product
andor
viru
replic
order
analyz
magnitud
ifn
respons
level
mrna
quantifi
qrtpcr
subcellular
local
examin
immunofluoresc
cours
infect
moi
result
infect
cell
measur
mrna
level
induc
hastv
peak
hpi
lower
induc
polyi
c
transfect
fig
sinc
transfect
effici
cell
low
polyi
c
transfect
result
cell
nuclear
produc
mrna
fig
compar
total
level
mrna
produc
polyi
ctransfect
cultur
level
produc
infect
cultur
would
seem
latter
cultur
either
infect
cell
produc
low
level
mrna
mrna
would
produc
number
infect
cell
costain
viral
structur
protein
show
hastvinfect
cell
nuclear
hpi
fig
hpi
percentag
cell
nuclear
increas
case
close
percentag
higher
infect
cell
moi
maximum
hpi
fig
hpi
cell
damag
due
infect
strong
allow
proper
interpret
data
fig
hpi
local
cytoplasm
hastvinfect
cell
data
shown
togeth
result
indic
despit
high
number
hastvinfect
cell
ifn
respons
infect
cultur
attenu
determin
transcript
induc
hastv
could
result
product
cell
releas
type
ifn
measur
presenc
antivir
activ
supernat
hastvinfect
cell
two
differ
moi
use
viru
infect
reduct
bioassay
use
treatment
type
ifn
refer
control
fig
order
make
sure
residu
hastv
would
remain
supernat
sampl
inactiv
uv
incub
prior
assay
total
viral
inactiv
confirm
lack
posit
cell
analysi
antivir
activ
emcv
could
detect
supernat
hastvinfect
cell
start
hpi
suggest
activ
gene
result
protein
product
secret
extracellular
environ
determin
product
viral
replic
requir
induct
innat
respons
cell
inocul
infecti
hastv
equival
amount
uvinactiv
viru
fig
differ
observ
viral
dose
confirm
rtqpcr
antivir
activ
supernat
cultur
never
observ
cell
infect
uvinactiv
virus
even
higher
moi
data
shown
indic
viral
replic
essenti
cell
activ
antivir
respons
order
determin
whether
block
intracellular
ifn
defens
mechan
benefit
hastv
replic
effect
treatment
cell
inhibitor
examin
aminopyrimidin
compound
inhibit
catalyt
activ
tankbind
kinas
kinas
epsilon
block
phosphoryl
well
pretreat
dmso
untreat
control
hour
infect
moi
infect
dmso
untreat
ad
cultur
media
hastv
product
measur
result
show
treatment
cell
result
signific
increas
total
hastv
rna
produc
well
amount
infecti
progeni
releas
supernat
compar
untreat
cell
tabl
howev
quantif
total
capsid
protein
elisa
indic
increas
compar
untreat
cell
suggest
although
higher
amount
viral
capsid
protein
produc
half
protein
abl
fulli
convert
infecti
virion
order
understand
whether
hastv
replic
sensit
ifn
cell
pretreat
uml
type
ifn
hour
infect
three
differ
moi
emcv
rv
use
control
ifnsensit
viru
ifnresist
viru
respect
number
hastvinfect
cell
observ
hpi
slightli
reduc
ifn
treatment
fig
viru
progeni
releas
supernat
measur
hastv
qrtpcr
emcv
rv
yield
measur
titrat
vero
cell
respect
reduct
hastv
replic
ifn
pretreat
signific
case
p
averag
reduct
log
less
observ
emcv
fig
expect
rv
affect
ifntreat
order
examin
whether
infect
hastv
inhibit
abil
cell
produc
respons
treatment
polyi
c
cell
mockinfect
infect
hastv
moi
transfect
polyi
c
hpi
twentyfour
hour
later
total
rna
analyz
qrtpcr
determin
level
mrna
induct
supernat
cell
collect
measur
antivir
activ
use
viru
infect
reduct
bioassay
cell
infect
rotaviru
moi
known
block
ifn
respons
use
posit
control
result
suggest
hastv
infect
abl
disrupt
innat
immun
sens
pathway
induc
polyi
c
fig
previou
infect
rv
abl
reduc
mrna
level
produc
polyi
c
transfect
although
differ
statist
signific
fig
hastv
rv
yield
similar
mocktransfect
well
well
transfect
polyi
c
data
shown
expect
antivir
activ
supernat
cultur
hpi
could
detect
cell
transfect
polyi
c
respons
could
reduc
presenc
rotaviru
infect
fig
higher
percentag
infect
cell
correl
higher
level
transepitheli
resist
ter
disrupt
higher
level
respons
type
ifn
caus
chang
ter
sinc
describ
hastv
infect
increas
barrier
permeabl
differenti
cell
examin
whether
correl
disrupt
intestin
barrier
number
infect
cell
respons
cell
differenti
polar
semiperm
insert
infect
apic
moi
experi
viru
inoculum
activ
trypsin
order
preserv
cell
monolay
activ
respons
measur
qrtpcr
normal
versu
gapdh
level
hpi
total
cellular
rna
describ
ter
level
measur
everi
h
hpi
percentag
infect
cell
calcul
well
immunofluoresc
assay
imag
analysi
field
reach
case
even
use
moi
probabl
due
fact
virus
preactiv
trypsin
infect
shown
fig
signific
reduct
ter
level
achiev
well
cell
monolay
infect
posit
correl
also
observ
percentag
ter
reduct
level
respons
fig
howev
incub
cell
uml
type
ifn
affect
ter
suggest
increas
cellular
permeabl
would
caus
viral
compon
cellular
factor
differ
type
ifn
sinc
virus
contain
differ
variant
associ
higher
replic
phenotyp
higher
level
viru
shed
stool
evalu
whether
variabl
influenc
magnitud
respons
cell
infect
moi
differ
hastv
mutant
differ
hvr
activ
measur
qrtpcr
normal
versu
gapdh
averag
number
viral
genom
copi
per
infect
cell
estim
quantifi
total
hastv
rna
qrtpcr
normal
number
infect
cell
within
well
averag
number
log
hastv
genom
copi
per
infect
cell
hastviv
hastvvi
hastvxii
respect
result
shown
fig
indic
differ
hastv
mutant
term
activ
level
respons
cell
infect
hastv
contain
genotyp
iv
lower
ifn
respons
induc
mutant
hastvvi
xii
especi
number
hastv
genom
per
infect
cell
high
work
examin
type
ifn
respons
statu
hastvinfect
cell
find
demonstr
hastv
infect
induc
strong
type
ifn
respons
evidenc
fact
mrna
detect
viral
replic
taken
place
low
level
compar
level
mrna
produc
infect
cultur
high
proport
infect
cell
produc
polyi
ctransfect
well
seem
either
infect
cell
produc
low
level
mrna
low
proport
infect
cell
produc
higher
amount
mrna
consist
latter
idea
low
percentag
infect
cell
show
transloc
nucleu
suggest
ifn
induct
take
place
infect
cell
although
complet
rule
synthesi
may
occur
independ
activ
work
hypothesi
ifnb
mrna
would
produc
within
everi
infect
cell
addit
nuclear
transloc
occur
late
time
postinfect
antivir
activ
supernat
infect
cell
detect
h
infect
confirm
case
ifn
product
take
place
late
stage
viral
replic
cycl
requir
infecti
virus
final
examin
abil
hastv
inhibit
ifn
respons
induc
polyi
c
transfect
observ
hastv
infect
abl
block
abil
cell
respond
dsrna
observ
wellstudi
ssrna
virus
hastv
behavior
would
similar
describ
virus
rhinoviru
mous
hepat
viru
taken
togeth
result
may
explain
observ
hastv
capsid
act
inhibitor
complement
activ
intracellular
uptak
complement
factor
bound
viral
particl
may
trigger
innat
immun
respons
within
cell
sinc
fb
ad
postinfect
medium
experi
plausibl
activ
innat
respons
delay
due
action
hastv
capsid
limit
deposit
complement
factor
viral
surfac
addit
mechan
may
also
contribut
minim
ifn
product
within
hastvinfect
cell
although
activ
antagonist
type
ifn
respons
character
wellstudi
gastroenter
virus
rotaviru
review
viral
countermeasur
limit
cellular
antivir
respons
may
also
achiev
sever
mechan
tightli
control
viru
transcript
replic
minim
product
dsrna
encapsid
form
viral
rna
produc
within
cell
protect
end
rna
cap
structur
vpg
protein
recognit
rigi
replic
within
intracellular
membran
vesicl
hide
viral
rna
cytoplasm
cellular
innat
recognit
machineri
recent
work
laboratori
experiment
confirm
hastv
genom
coval
link
vpg
protein
end
larg
membran
rearrang
observ
hastvinfect
cell
viru
aggreg
surround
doublemembran
vacuol
inde
hastv
assembl
seem
start
cellular
membran
site
nonstructur
protein
replic
genom
cell
fraction
studi
shown
posit
neg
hastv
rna
also
nonstructur
protein
local
vesicl
capsid
protein
get
anchor
synthesi
despit
strategi
minim
innat
antivir
respons
would
express
late
stage
viral
replic
cycl
addit
exogen
ifn
abl
partial
reduc
viral
replic
drug
inhibit
ifn
signal
enhanc
viru
replic
suggest
hastv
may
regard
ifnsensit
virus
inde
innat
respons
shown
play
role
control
astv
replic
avail
anim
model
turkey
astv
primari
infect
control
express
induc
nitric
oxid
synthas
ino
subsequ
increas
innat
immun
mediat
mice
astv
replic
intestin
viral
shed
significantli
higher
wildtyp
mice
pathway
ino
activ
shown
import
control
viral
gastroenter
agent
norovirus
also
sensit
exogen
ifn
also
recent
type
iii
ifn
gain
import
key
mediat
antivir
immun
intestin
infect
although
activ
antivir
pathway
type
ifn
act
differ
receptor
primarili
express
gastrointestin
mucos
epithelia
interestingli
determin
intestin
epitheli
antivir
host
defens
acut
rotaviru
infect
persist
infect
associ
murin
norovirus
therapeut
potenti
experiment
proven
mice
although
still
know
whether
may
also
critic
control
hastv
infect
confirm
synthesi
mrna
take
place
within
hastvinfect
cell
data
shown
futur
experi
laboratori
aim
character
respons
cellular
level
besid
complet
elucid
mechan
use
hastv
attenu
cellular
type
ifn
respons
would
also
import
examin
whether
interplay
occur
express
mrna
activ
apoptosi
within
cell
apoptosi
shown
requir
late
stage
infect
matur
hastv
capsid
cellular
caspas
play
activ
role
releas
virion
infect
cell
nonlyt
mechan
although
motif
found
potenti
apoptosi
inductor
apoptosi
may
also
consequ
cellular
ifn
respons
action
type
ifn
within
cell
promot
express
interferon
stimul
gene
isg
proapoptot
function
addit
certain
cell
type
cellular
player
ifn
signal
pathway
may
also
activ
caspas
apoptosi
independ
ifn
studi
ifn
respons
inhibit
inhibitor
observ
increas
viral
rna
infecti
titer
increas
total
capsid
protein
measur
endpoint
dilut
elisa
assay
tabl
suggest
inhibit
ifn
allow
viru
replic
higher
titer
also
result
high
proport
capsid
may
properli
assembl
encapsid
andor
matur
although
experi
perform
plausibl
late
stage
infect
hastv
may
take
advantag
cellular
ifn
respons
activ
trigger
apoptot
signal
specif
caspas
requir
late
step
capsid
morphogenesi
virion
releas
cell
final
report
differ
level
ifnb
activ
upon
infect
hastv
mutant
differ
gene
previou
experi
laboratori
describ
differ
variant
correl
differ
viral
replic
phenotyp
cell
cultur
well
viru
shed
patient
shown
compar
hastvvi
hastvxii
hastviv
abl
replic
cell
higher
titer
without
induc
strong
cellular
innat
respons
although
experi
done
includ
fb
cultur
media
could
activ
innat
respons
complement
deposit
viral
particl
either
input
particl
de
novo
produc
particl
hypothesi
either
directli
indirectli
genotyp
influenc
level
ifn
respons
induc
within
cell
consist
idea
viral
stock
produc
laboratori
absenc
fb
hastviv
higher
viral
titer
stock
produc
genotyp
data
shown
clinic
isol
correspond
genotyp
iv
associ
persist
gastroenter
thu
although
link
variabl
ifn
respons
may
indirect
result
highlight
variabl
within
protein
may
clinic
implic
term
pathogen
potenti
role
protein
antivir
target
